Journal
EBIOMEDICINE
Volume 67, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ebiom.2021.103354
Keywords
Adoptive cell therapy; Immunotherapy; Gene editing; Non-viral delivery
Funding
- US National Institutes of Health (NIH) Director's New Innovator Award [DP2 TR002776]
- Burroughs Wellcome Fund Career Award at the Scientific Interface (CASI)
- National Institutes of Health [R01CA241661, R37CA244911, R01DK123049, UL1TR001878]
- Institute for Translational Medicine and Therapeutics (ITMAT) Transdisciplinary Program in Translational Medicine and Therapeutics
- Tau Beta Pi Graduate Research Fellowship
- NIH Training in HIV Pathogenesis T32 Program [T32 AI007632]
- Littlejohn Undergraduate Research Program
Ask authors/readers for more resources
Genetic engineering has transformed cancer immunotherapy by modifying primary T cells to enhance their therapeutic potential, with studies and clinical trials supporting the effectiveness of this approach.
While initial approaches to adoptive T cell therapy relied on the identification and expansion of rare tumour-reactive T cells, genetic engineering has transformed cancer immunotherapy by enabling the modification of primary T cells to increase their therapeutic potential. Specifically, gene editing technologies have been utilized to create T cell populations with improved responses to antigens, lower rates of exhaustion, and potential for use in allogeneic applications. In this review, we provide an overview of T cell therapy gene editing strategies and the delivery technologies utilized to genetically engineer T cells. We also discuss recent investigations and clinical trials that have utilized gene editing to enhance the efficacy of T cells and broaden the application of cancer immunotherapies. (C) 2021 The Author(s). Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available